sma

Branaplam (LMI 070) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.

SMA-12b is an analog of the immunomodulatory parasite product ES-62 that has immunomodulatory activity, can modify the expression of many inflammatory response genes, increase the expression of many genes related to antioxidant responses, and can be used in the study of rheumatoid arthritis (RA) and other autoimmune diseases.

SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.

Rosmarinic acid (Labiatenic acid) is widely found in plants and has antioxidant, anti-inflammatory, and antibacterial activities. It inhibits MAO-A, MAO-B, and COMT with IC50 of 50.1, 184.6, and 26.7 μM respectively.

Bismaleimide (XU 292A) has heat resistance, oxidation resistance and radiation resistance, and can be used to prepare electrical insulation materials, wear-resistant materials, reinforced plastic additives, grinding wheel adhesives, etc.

Losmapimod (GSK-AHAB) (GW856553X; SB856553; GSK-AHAB) is a specific, potent, and orally active p38 MAPK inhibitor (pKi: 8.1 7.6 for p38α β).

Rosmanol has antioxidant activity, it can activate the antioxidant response element. Rosmanol has biphasic modulation of GABAA receptors, demonstrates CNS activity in mouse models of antinociception, antidepressant and anxiolysis. Rosmanol potently induce

SMANT hydrochloride (N-(4-bromophenyl)-3-(3,5-dimethylpiperidin-1-yl)propanamide hydrochloride) is an antagonist of Smoothened accumulation.

SMARCA-BD ligand 1 for Protac dihydrochloride binds to the BAF ATPase subunit SMARCA2 and is used for degrading SMARCA2 based on PROTAC.

SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3), and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM, and 13 nM, respectively.

Small Cardioactive Peptide B (SCPB), a neurally active peptide, stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with EC50s of 0.1 and 1.0 μM, respectively.

Xylosmacin is a biochemical.

Rosmaquinone is a useful organic compound for research related to life sciences and the catalog number is T126198.

Lu-AAZTA-NI-PSMA-093, a bivalent radiopharmaceutical agent designed for prostate cancer treatment, improves tumor targeting and retention. This is achieved by integrating a hypoxia-sensitive nitroimidazole (NI) group with a prostate-specific membrane antigen (PSMA) targeting moiety.

SMARCA2 degrader-3 (compound I-323) is a PROTAC molecule designed to target and degrade the SMARCA2 protein. In A549 cells, it exhibits a degradation half-maximal concentration (DC50) of less than 100 nM and achieves a maximum degradation rate (Dmax%) greater than 90% after 24 hours of treatment.

SMARCA2 4-IN-1 (compound 1) serves as a potent inhibitor of both SMARCA2 and SMARCA4, with IC50 values of 3.8 µM and 1.7 µM, respectively.

SMARCA2 degrader-1 (compound I-321) is a PROTAC degrader with a DC50 for SMARCA of less than 100nM, featuring a structure that incorporates a SMARCA inhibitor, a linker, and an E3 ligase ligand.

SMARCA2 ligand-6 is a PROTAC-targeted protein ligand.

SMARCA2-IN-8 (Compound 13) is an orally effective inhibitor targeting the SWI SNF chromatin remodeling complexes SMARCA2 (also known as Brahma homolog, BRM) and SMARCA4 (also known as Brahma-related gene 1, BRG1), with IC50 values of 5 nM and 6 nM respectively. This compound inhibits the proliferation of SMARCA2-mutant SKMEL5 cancer cells with an AAC50 of 5 nM and downregulates the expression of the SMARCA2-dependent gene KRT80, showing an AAC50 of 10 nM. Additionally, SMARCA2-IN-8 demonstrates antitumor efficacy and favorable pharmacokinetic properties in mice.

SMARCA2-IN-7 (compound 12) acts as a dual inhibitor for both BRM and BRG1 with IC50 values less than 0.005, exhibiting antitumor proliferation effects. It inhibits tumor proliferation in SKMEL5 cells lacking BRG1 with an AAC50 of 13 nM. Additionally, in H1299 cells, it suppresses cell proliferation activity of KRT880 with an AAC50 of 42 nM.

PROTAC SMARCA2 4-degrader-26 is a PROTAC targeting the SMARCA2 4 proteins. It is composed of the ligand for PROTAC targeting proteins, 2-(4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)acetic acid, an E3 ligase component (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, and a PROTAC linker (S)-2-Amino-3,3-dimethylbutanoic acid. The coupled complex of the E3 ubiquitin ligase ligand + Linker is referred to as (S,R,S)-AHPC.

PROTAC SMARCA2 4-degrader-29 (Compound I-279) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI SNF complex. In A549 cells, this compound effectively degrades SMARCA2 with a DC50 value of less than 100 nM, and similarly degrades SMARCA4 in MV411 cells with a DC50 under 100 nM.

PROTAC SMARCA2-degrader-36 (compound 38) is an SMARCA2 degrader that achieves a 99% degradation rate at 100 nM in H929 cells. It possesses antiproliferative activity and is used in cancer research.

SMARCA2-IN-1 (Compound I-19) serves as an inhibitor of the SWI SNF chromatin remodeling complex SMARCA2, exhibiting an IC50 value greater than 1000 nM in H1299 cells.